73 related articles for article (PubMed ID: 9494539)
1. Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer.
Stickeler E; Möbus VJ; Kieback DG; Kohlberger P; Runnebaum IB; Kreienberg R
Anticancer Res; 1997; 17(6D):4395-8. PubMed ID: 9494539
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines.
Stickeler E; Runnebaum IB; Möbus VJ; Kieback DG; Kreienberg R
Anticancer Res; 1997; 17(3C):1871-6. PubMed ID: 9216637
[TBL] [Abstract][Full Text] [Related]
3. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors.
Yoshida K; Bolodeoku J; Sugino T; Goodison S; Matsumura Y; Warren BF; Toge T; Tahara E; Tarin D
Cancer Res; 1995 Oct; 55(19):4273-7. PubMed ID: 7545538
[TBL] [Abstract][Full Text] [Related]
4. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.
Cannistra SA; DeFranzo B; Niloff J; Ottensmeir C
Clin Cancer Res; 1995 Mar; 1(3):333-42. PubMed ID: 9815989
[TBL] [Abstract][Full Text] [Related]
5. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.
Abetamann V; Kern HF; Elsässer HP
Clin Cancer Res; 1996 Sep; 2(9):1607-18. PubMed ID: 9816340
[TBL] [Abstract][Full Text] [Related]
7. Splice variant expression of CD44 in patients with breast and ovarian cancer.
Sanchez Lockhart M; Hajos SE; Basilio FM; Mongini C; Alvarez E
Oncol Rep; 2001; 8(1):145-51. PubMed ID: 11115587
[TBL] [Abstract][Full Text] [Related]
8. Transcription and expression of CD44 variant exons by oro-pharyngeal squamous cell carcinomas.
Bloor BK; Rajarajan A; Jaafary-Haghighat K; Odell EW
Int J Oncol; 2002 Oct; 21(4):907-13. PubMed ID: 12239634
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression.
Hayes GM; Dougherty ST; Davis PD; Dougherty GJ
Cancer Gene Ther; 2004 Dec; 11(12):797-807. PubMed ID: 15359288
[TBL] [Abstract][Full Text] [Related]
10. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities.
Matsumura Y; Sugiyama M; Matsumura S; Hayle AJ; Robinson P; Smith JC; Tarin D
J Pathol; 1995 Sep; 177(1):11-20. PubMed ID: 7472774
[TBL] [Abstract][Full Text] [Related]
11. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W; Krill D; Dhir R; Becich MJ; Dong JT; Frierson HF; Isaacs WB; Isaacs JT; Gao AC
Cancer Res; 1999 May; 59(10):2329-31. PubMed ID: 10344738
[TBL] [Abstract][Full Text] [Related]
13. Expression of splicing factors in human ovarian cancer.
Fischer DC; Noack K; Runnebaum IB; Watermann DO; Kieback DG; Stamm S; Stickeler E
Oncol Rep; 2004 May; 11(5):1085-90. PubMed ID: 15069551
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.
Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W
Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3.
Kuniyasu H; Oue N; Tsutsumi M; Tahara E; Yasui W
Clin Cancer Res; 2001 Dec; 7(12):4067-72. PubMed ID: 11751503
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
17. Absence of p51 alteration in human ovarian cancer.
Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
[TBL] [Abstract][Full Text] [Related]
18. Clear cell carcinoma of the ovary: characterization of its CD44 isoform repertoire.
Sancho-Torres I; Mesonero C; Miller Watelet JL; Gibbon D; Rodríguez-Rodríguez L
Gynecol Oncol; 2000 Nov; 79(2):187-95. PubMed ID: 11063642
[TBL] [Abstract][Full Text] [Related]
19. Preferential overexpression of CD44v5 in advanced gastric carcinoma Goseki grades I and III.
Stachura J; Krzeszowiak A; Popiela T; Urbańczyk K; Pituch-Noworolska A; Wieckiewicz J; Zembala M
Pol J Pathol; 1999; 50(3):155-61. PubMed ID: 10624117
[TBL] [Abstract][Full Text] [Related]
20. Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells.
Yang W; Toffa SE; Lohn JW; Seifalian AM; Winslet MC
Gynecol Oncol; 2005 Feb; 96(2):430-8. PubMed ID: 15661232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
